UNSPSC 51172100: Antispasmodics

This classification denotes agents that inhibit the actions of the parasympathetic nervous system. the major group of drugs used therapeutically for this purpose is the muscarinic antagonists.

UNSPSC 51172100 Antispasmodics, a Class code, covers drug testing and pharmaceutical supply services that state and local governments procure for correctional supervision, health and human services, and multistate cooperative purchasing programs. Recent solicitations show state and local buyers acquiring specimen collection and drug testing services for offender monitoring, direct-to-manufacturer prescription fulfillment capabilities for state pharmacy benefit programs, and generic pharmaceutical and over-the-counter products through cooperative purchasing alliances. The issuing bodies include county correctional departments, state health and human services commissions, and multistate cooperative procurement organizations administering contracts on behalf of participating state and local agencies.

Activity concentrates in Texas and Minnesota. Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026, for offender specimen collection and drug testing services with proposals due July 23, 2026, specifying approximately 25,031 annual tests across five-panel and six-panel screens with lab certification from SAMHSA, TX DPS, or CAP, at an estimated contract value of $600,000 over two years with three optional one-year renewals. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program to improve fulfillment efficiency outside traditional pharmacy benefit manager channels, though no award values or formal evaluation criteria were specified at the RFI stage. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, requiring vendors to supply through three authorized wholesalers with pricing weighted 75 percent in evaluation and contract effective July 1, 2026.